Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

[1]  S. Highlander,et al.  A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. , 2020, The oncologist.

[2]  Michael D. Nyquist,et al.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. , 2020, Cell reports.

[3]  L. Lipshultz,et al.  Selective androgen receptor modulators: the future of androgen therapy? , 2020, Translational andrology and urology.

[4]  M. Yamaoka,et al.  A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys , 2020, Pharmacology research & perspectives.

[5]  P. Nelson,et al.  Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. , 2020, European urology.

[6]  E. Antonarakis,et al.  Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. , 2020, The Prostate.

[7]  Michael D. Nyquist,et al.  Molecular determinants of response to high dose androgen therapy in prostate cancer. , 2019, JCI insight.

[8]  Michael D. Nyquist,et al.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. , 2019, The Journal of clinical investigation.

[9]  Steven Henikoff,et al.  Improved CUT&RUN chromatin profiling tools , 2019, eLife.

[10]  J. Henck,et al.  Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients , 2018, Andrology.

[11]  M. Yamaoka,et al.  Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f , 2017, PloS one.

[12]  Katsuji Aikawa,et al.  Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models. , 2017, Oncology letters.

[13]  P. Deuster,et al.  Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet , 2017, JAMA.

[14]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[15]  R. V. Clark,et al.  Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women , 2017, British journal of clinical pharmacology.

[16]  P. Werbrouck,et al.  Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. , 2017, European urology.

[17]  J. Dalton,et al.  Development of selective androgen receptor modulators (SARMs) , 2017, Molecular and Cellular Endocrinology.

[18]  Michael D. Nyquist,et al.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155 , 2017, Molecular Cancer Research.

[19]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[20]  Kam Y. J. Zhang,et al.  The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide , 2016, Molecular Cancer Therapeutics.

[21]  J. Dalton,et al.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin , 2016, Investigational New Drugs.

[22]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[23]  James L. Chen,et al.  Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer , 2016, Oncotarget.

[24]  R. Hales,et al.  Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation , 2016, Clinical Cancer Research.

[25]  J. Carroll,et al.  Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes , 2016, Nature Protocols.

[26]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[27]  Qing-Yu He,et al.  ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization , 2015, Bioinform..

[28]  Jun Luo,et al.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study , 2015, Science Translational Medicine.

[29]  J. Heidelbaugh,et al.  Adverse effects of testosterone replacement therapy: an update on the evidence and controversy , 2014, Therapeutic advances in drug safety.

[30]  M. Bock,et al.  3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration. , 2014, Journal of medicinal chemistry.

[31]  H. Klocker,et al.  A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling , 2014, Molecular Cancer.

[32]  D. Powell,et al.  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators. , 2014, Journal of medicinal chemistry.

[33]  G. Grunwald,et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.

[34]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[35]  James A. DeCaprio,et al.  The DREAM complex: master coordinator of cell cycle-dependent gene expression , 2013, Nature Reviews Cancer.

[36]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[37]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[38]  A. Dobs,et al.  Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. , 2013, The Lancet. Oncology.

[39]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[40]  Anushya Muruganujan,et al.  PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..

[41]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[42]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[43]  P. Nelson.  Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[45]  Chih-Pin Chuu,et al.  Androgen suppresses proliferation of castration‐resistant LNCaP 104‐R2 prostate cancer cells through androgen receptor, Skp2, and c‐Myc , 2011, Cancer science.

[46]  J. Dalton,et al.  The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial , 2011, Journal of cachexia, sarcopenia and muscle.

[47]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[48]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[49]  S. Narayan,et al.  Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. , 2010, The American journal of cardiology.

[50]  A. Jette,et al.  Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[51]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[52]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[53]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[54]  G. Bubley,et al.  Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.

[55]  J. Dalton,et al.  Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands , 2006, Pharmaceutical Research.

[56]  Tzu-Ming Chu,et al.  Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. , 2006, Molecular endocrinology.

[57]  M. Rosenfeld,et al.  Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. Kazmin,et al.  Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. , 2003, Cancer research.

[60]  C. Higano.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. , 2003, Urology.

[61]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[63]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[64]  R. Hiipakka,et al.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[66]  C. Drake,et al.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. , 2018, The Lancet. Oncology.

[67]  Duane D. Miller,et al.  Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling , 2014, PloS one.

[68]  Shalender Bhasin,et al.  The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[69]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.